Analysts Anticipate Tabula Rasa HealthCare Inc (TRHC) Will Post Quarterly Sales of $52.97 Million

Brokerages predict that Tabula Rasa HealthCare Inc (NASDAQ:TRHC) will post $52.97 million in sales for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Tabula Rasa HealthCare’s earnings. The lowest sales estimate is $52.50 million and the highest is $54.38 million. Tabula Rasa HealthCare posted sales of $33.27 million during the same quarter last year, which would indicate a positive year over year growth rate of 59.2%. The company is expected to issue its next quarterly earnings report on Monday, November 5th.

On average, analysts expect that Tabula Rasa HealthCare will report full-year sales of $198.29 million for the current financial year, with estimates ranging from $195.00 million to $203.28 million. For the next financial year, analysts expect that the business will report sales of $244.53 million, with estimates ranging from $230.30 million to $264.93 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover Tabula Rasa HealthCare.

Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.12. The firm had revenue of $48.60 million during the quarter, compared to the consensus estimate of $46.73 million. Tabula Rasa HealthCare had a positive return on equity of 4.55% and a negative net margin of 16.78%.

A number of research firms recently weighed in on TRHC. BidaskClub downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 15th. Robert W. Baird boosted their target price on Tabula Rasa HealthCare from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, June 18th. Piper Jaffray Companies boosted their target price on Tabula Rasa HealthCare to $71.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 8th. Zacks Investment Research upgraded Tabula Rasa HealthCare from a “hold” rating to a “buy” rating and set a $74.00 target price for the company in a research report on Saturday, August 11th. Finally, Stifel Nicolaus began coverage on Tabula Rasa HealthCare in a research report on Tuesday, September 11th. They issued a “hold” rating and a $95.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $69.75.

NASDAQ:TRHC opened at $81.19 on Friday. The company has a market capitalization of $1.61 billion, a P/E ratio of -2,029.75, a PEG ratio of 6.00 and a beta of 2.71. Tabula Rasa HealthCare has a 1-year low of $24.24 and a 1-year high of $91.16. The company has a quick ratio of 0.33, a current ratio of 0.36 and a debt-to-equity ratio of 0.11.

In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction that occurred on Monday, September 17th. The stock was sold at an average price of $79.80, for a total value of $638,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 48,000 shares of company stock valued at $3,473,920 in the last 90 days. 14.00% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in TRHC. BlackRock Inc. increased its stake in Tabula Rasa HealthCare by 284.6% in the 1st quarter. BlackRock Inc. now owns 1,634,528 shares of the company’s stock worth $63,419,000 after purchasing an additional 1,209,501 shares during the period. NN Investment Partners Holdings N.V. purchased a new position in Tabula Rasa HealthCare in the 2nd quarter worth approximately $29,439,000. Granite Investment Partners LLC increased its stake in Tabula Rasa HealthCare by 1,969.2% in the 2nd quarter. Granite Investment Partners LLC now owns 212,010 shares of the company’s stock worth $13,532,000 after purchasing an additional 201,764 shares during the period. Braun Stacey Associates Inc. increased its stake in Tabula Rasa HealthCare by 199.0% in the 2nd quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock worth $19,219,000 after purchasing an additional 200,394 shares during the period. Finally, Jennison Associates LLC increased its stake in Tabula Rasa HealthCare by 29.5% in the 2nd quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock worth $48,373,000 after purchasing an additional 172,693 shares during the period. 75.15% of the stock is currently owned by institutional investors and hedge funds.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.

See Also: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply